Trial Profile

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Sep 2025 According to an Almirall, S.A. media release, data from this study will be presented at the 34th European Academy of Dermatology and Venereology Congress (EADV) taking place from September 17 to 20 in Paris, France.
17 Sep 2025 Results presented in the Almirall, S.A. Media Release.
01 Dec 2024 Results of subset pooled anaylsis(ADvocate1, ADvocate2, and ADhere) evaluating 16-week physician- and patient-reported outcomes of lebrikizumab in the adolescent patients, published in the Journal of Dermatological Treatment

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com